| Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
The 2024 Annual Meeting of Stockholders of Plus Therapeutics, Inc. (the “Company”) was held on August 15, 2024 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on four proposals, as described in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on July 10, 2024 (the “Proxy Statement”).
The Company had 5,704,219 shares of common stock issued and outstanding at the close of business on June 25, 2024, the record date for eligibility to vote at the Annual Meeting. The holders of 2,484,122 shares of the Company’s issued and outstanding common stock were represented in person virtually or represented by valid proxy at the Annual, constituting a quorum.
The vote results detailed below represent final results as certified by the inspector of elections.
Proposal No. 1 – Election of Directors.
The Company’s stockholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company to hold office for a term expiring at the Company’s Annual Meeting of Stockholders in 2025 and until each such person’s successors is duly elected and qualified, or until his or her earlier death, resignation or removal:
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Votes For |
|
|
Votes Withheld |
|
|
Broker Non-Votes |
|
| Howard Clowes |
|
|
1,175,799 |
|
|
|
107,484 |
|
|
|
1,200,839 |
|
| An van Es-Johansson, M.D. |
|
|
1,178,415 |
|
|
|
104,868 |
|
|
|
1,200,839 |
|
| Richard J. Hawkins |
|
|
1,159,421 |
|
|
|
123,862 |
|
|
|
1,200,839 |
|
| Marc H. Hedrick, M.D. |
|
|
1,183,165 |
|
|
|
100,118 |
|
|
|
1,200,839 |
|
| Robert Lenk, Ph.D. |
|
|
1,176,767 |
|
|
|
106,516 |
|
|
|
1,200,839 |
|
| Greg Petersen |
|
|
1,183,545 |
|
|
|
99,738 |
|
|
|
1,200,839 |
|
Proposal No. 2 – Ratification of Appointment of Independent Registered Public Accounting Firm.
The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s registered public accounting firm for the 2024 fiscal year. The votes regarding this proposal were as follows:
|
|
|
|
|
|
|
| Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
| 2,434,053 |
|
44,854 |
|
5,215 |
|
0 |
Proposal No. 3 – Advisory Vote on the Compensation of Our Named Executive Officers.
The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows:
|
|
|
|
|
|
|
| Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
| 1,115,004 |
|
163,917 |
|
4,362 |
|
1,200,839 |
Proposal No. 4 – Amendment and Restatement of the Company’s 2020 Stock Incentive Plan.
The Company’s stockholders approved the fourth amendment and restatement of the Company’s 2020 Stock Incentive Plan. The votes regarding this proposal were as follows:
|
|
|
|
|
|
|
| Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
| 1,097,650 |
|
182,432 |
|
3,201 |
|
1,200,839 |